Changing the practice of cardiovascular medicine

Atherosclerosis Supplements

Volumn 2, Issue 1, 2001, Pages 27-30

  Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiac; Morbidity; Mortality; Myocardial infarction

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; GATIFLOXACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CORONARY RISK; DRUG EFFICACY; EUROPE; EVIDENCE BASED MEDICINE; HOSPITAL DISCHARGE; HUMAN; HYPERCHOLESTEROLEMIA; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED STATES; ADULT; AGED; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; MIDDLE AGED; PATIENT COMPLIANCE; REVIEW; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0035260815     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(00)00007-6     Document Type: Conference Paper

References (30)

1. EUROASPIRE: a European Society of Cardiology survey on secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events (published erratum appears in Eur. Heart J. 1998; 19: 357). Eur. Heart J. 18:1997;1569-1582.
2. Cambou JP, Grenier O, Ferrieres J, Danchin N. Secondary prevention of patients with acute coronary syndrome in France; the PREVENIR survey. Lancet Conference (Abstr.), 1999; p. 73 Copenhagen.
3. de Valasco JA, Cosin J, Sendon JL, De Teresa E, The PREVESE Study. Secondary prevention of myocardial infarction in Spain. Rev. Esp. Cardiol. 1997;50:406-415.
4. Heart and Stroke Statistical Update. 2001;American Heart Association, Dallas.
5. Keech A. Atherosclerosis (Suppl.). 136:1998;531.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
7. Sacks FM, Pfeffer MA, Moye LA for the Cholestrol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 1996;335:1001-1009.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl. J. Med. 339:1998;1349-1357.
9. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Gorup. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. 1995;333:1301-1307.
10. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS, J. Am. Med. Assoc. 279:1998;1615-1622.
11. Kesteloot H., Claeys G., Blanckaert N., Lesaffre E. Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin. Acta Cardiol. 2:1997;107-116.
12. Den Hartog F., Verheugt F.W.A. Early HMG-CoA reductase inhibition in acute coronary syndromes: preliminary data of the pravastatin in acute ischaemic syndromes study (PAIS). Eur. Heart J. 19:1998;2802.
13. Arntz H.R., Wunderlich W., Schnitzer L. The decisive importance of cholesterol lowering therapy for coronary lesions and clinical course immediately after an acute coronary event: short and long term results of a controlled study. Circulation (Abstr.). 98:(1):1998;1-45.
14. Kayikcioglu M., Turkoglu C., Kultursay H., Harum H., Can L. Combined use of pravastatin and thrombolytic agents in acute myocardial infarction. Pravastatin Turkish Trial. Circulation (Abstr.). 100:(1):1999;1-303.
15. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 99:1999;3227-3233.
16. Aronow H.D., Roe M.T., Lauer M.S., et al. Early and striking mortality reduction after acute coronary syndromes following lipid lowering therapy. J. Am. Coll. Cardiol. (Abstr.). 35:2000;411A.
17. Data on file, BMS.
18. Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med. 340:1999;115-126.
19. Danesh J., Collins R., Peto R. Chronic infection and coronary heart disease: is there a link? Lancet. 350:1997;430-436.
20. Libby P., Egan D., Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation. 96:1997;4095-4103.
21. Kuo C.C., Shor A., Campbell L.A., Fukushi H., Patton D.L., Grayston J.T. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J. Infect. Dis. 167:1993;841-849.
22. Muhlestein J.B., Hammond E.H., Carlquist J.F., et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J. Am. Coll. Cardiol. 27:1996;1555-1561.
23. Kuo C.C., Grayston J.T., Campbell L.A., Goo Y.A., Wissler R.W., Benditt E.P. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc. Natl. Acad. Sci. USA. 92:1995;6911-6914.
24. Fong I.W., Chiu B., Viira E., Fong M.W., Jang D., Mahony J. Rabbit model for Chlamydia pneumoniae infection. J. Clin. Microbiol. 35:1997;48-52.
25. Fong I.W. Value of animal models for Chlamydia pneumoniae-related atherosclerosis. Am. Heart J. 138:1999;512-513.
26. Muhlestein J.B., Anderson J.L., Hammond E.H., et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:1998;633-636.
27. Moazed T.C., Kuo C., Grayston J.T., Campbell L.A. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J. Infect. Dis. 175:1997;883-890.
28. Moazed T.C., Campbell L.A., Rosenfeld M.E., Grayston J.T., Kuo C.C. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J. Infect. Dis. 180:1999;238-241.
29. Shepherd J., Blauw G.J., Murphy M.B., et al. The design of a prospective study of Pravastatin in the Elderly at Risk. PROSPER Study Group. Am. J. Cardiol. 84:1999;1192-1197.
30. Braunwald E. PRINCE: design and rationale. Curr. Cardiol. Rev. 2:2000;1-5.